« back to directory

Company Profile

Zucero Therapeutics Ltd

  •  
  •  

About Zucero Therapeutics Ltd

Zucero Therapeutics is an Australian-based biotechnology company committed to the discovery and development of modified sugar compounds for the treatment of cancer. Pixatimod (PG545) has emerged as Zucero’s first clinical candidate and is classified as an immunomodulatory agent that enhances the host immune system’s ability to suppress cancer. Pixatimod has been shown to be well tolerated as a single agent in patients with advanced cancer and is currently being tested in combination with the immune checkpoint inhibitor Opdivo® for the treatment of advanced cancer with a focus on pancreatic cancer.